A Study to Evaluate RIST4721 in Hidradenitis Suppurativa (HS)

A Randomized, Double-blinded, Placebo-controlled, Phase 2a Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects With Hidradenitis Suppurativa

A Randomized, Double-blinded, Placebo-controlled, Phase 2a Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects with Hidradenitis Suppurativa

Inclusion Criteria:

• Diagnosis of HS for at least 1 year prior to screening
• HS lesions must be present in at least 2 distinct anatomic areas
• A total AN count (sum of abscesses and inflammatory nodules) > 6 across all anatomical sites at both the screening and baseline visits
• Willing to use contraception for the duration of the study

Exclusion Criteria:

• Presence of other skin conditions which may interfere with study assessments
• Presence of active, chronic or latent bacterial, viral, fungal mycobacterial infection (including latent TB) or history of infection within 4 weeks of screening
• Body Mass Index (BMI) >48kg/m2
• Breastfeeding or pregnant